{"id":42442,"date":"2021-05-11T10:45:47","date_gmt":"2021-05-11T14:45:47","guid":{"rendered":"https:\/\/www.simonssearchlight.org\/2021\/05\/11\/onze-deelnemers-verdeling-10-jarig-jubileum\/"},"modified":"2024-02-15T14:17:36","modified_gmt":"2024-02-15T19:17:36","slug":"onze-deelnemers-verdeling-10-jarig-jubileum","status":"publish","type":"post","link":"https:\/\/www.simonssearchlight.org\/nl\/2021\/05\/11\/onze-deelnemers-verdeling-10-jarig-jubileum\/","title":{"rendered":"Onze deelnemers: Verdeling 10-jarig jubileum"},"content":{"rendered":"<p>In de afgelopen 10 jaar heeft <span class=\"notranslate\">Simons Searchlight<\/span> zich ontwikkeld en omvat nu meer dan 150 genetische aandoeningen. Als onderdeel van ons 10-jarig onderzoek kijken we naar de deelnemers binnen onze gemeenschap.<\/p>\n<p style=\"padding-left: 30px;\">&#8220;<em>Door de nauwe samenwerking met gezinnen in al onze aandoeningen in de afgelopen 10 jaar, zien we \u00e9\u00e9n ding: hoewel elk kind een individu is, lijken we meer op elkaar dan dat we verschillen. Behandelingen voor ontwikkelingsproblemen in het bijzonder kunnen ge\u00efndividualiseerde beoordeling en precisiegeneeskunde vereisen, maar zullen ook worden gedreven door onze kracht in aantallen.&#8221;<\/em><\/p>\n<p style=\"padding-left: 30px;\"><strong>LeeAnne Green Snyder<br \/>\n<\/strong><strong>Gediplomeerd klinisch psycholoog, klinisch onderzoeker, Simons Zoeklicht<\/strong><\/p>\n<p>Tot nu toe hebben we meer dan 4.000 gezinnen geregistreerd in <span class=\"notranslate\">Simons Searchlight<\/span>. Zie hieronder voor het aantal registraties uitgesplitst per genetische aandoening. De eerste grafiek bevat genetische groepen met meer dan 20 geregistreerde families en de tweede grafiek bevat genetische groepen met 5 tot 19 geregistreerde families.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-10675\" src=\"https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053138\/n_families.jpg\" alt=\"\" width=\"1429\" height=\"863\" srcset=\"https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053138\/n_families.jpg 1429w, https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053138\/n_families-300x181.jpg 300w, https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053138\/n_families-768x464.jpg 768w, https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053138\/n_families-1024x618.jpg 1024w\" sizes=\"(max-width: 1429px) 100vw, 1429px\" \/><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-10676\" src=\"https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053141\/n_families2.jpg\" alt=\"\" width=\"1302\" height=\"842\" srcset=\"https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053141\/n_families2.jpg 1302w, https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053141\/n_families2-300x194.jpg 300w, https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053141\/n_families2-768x497.jpg 768w, https:\/\/cdn.simonssearchlight.org\/wp-content\/uploads\/2021\/05\/11053141\/n_families2-1024x662.jpg 1024w\" sizes=\"(max-width: 1302px) 100vw, 1302px\" \/><\/p>\n<p><span class=\"notranslate\">Simons Searchlight<\/span> deelnemers worden uitgenodigd om telefonisch een medisch anamnesegesprek (MHI) af te nemen met onze genetisch consulenten. Hieronder vind je twee tabellen met informatie van deelnemers aan Simons Zoeklicht. Gegevens uit ander gepubliceerd onderzoek zijn niet opgenomen. Deze tabellen bevatten mensen met varianten die zijn geclassificeerd als pathogeen of waarschijnlijk pathogeen. Varianten van onzekere betekenis (VUS) zijn niet opgenomen. Mensen met een VUS worden uitgenodigd om deel te nemen en we beoordelen varianten die als VUS zijn geclassificeerd jaarlijks opnieuw.<\/p>\n<p>&nbsp;<\/p>\n<p>De eerste tabel<strong>(Tabel 1<\/strong>) bevat genetische groepen waarvan de medische voorgeschiedenis bij minstens 10 deelnemers is afgenomen. Tabel 1 bevat het percentage (%) mensen die een autismespectrumstoornis (ASS), ontwikkelingsachterstand of verstandelijke beperking (DD\/ID) en epileptische aanvallen rapporteerden.<\/p>\n<p><strong>Tabel 1. Genetische groepen met 10 of meer voltooide MHI&#8217;s (22 groepen).<\/strong><\/p>\n<table style=\"width: 100%; border: 1px solid black;\">\n<tbody>\n<tr>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>Gen-\/kopienummervariant<\/strong><\/td>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>Aantal mensen met MHI&#8217;s<\/strong><\/td>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>ASS (aantal) %<\/strong><\/td>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>DD\/ID (aantal) %<\/strong><\/td>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>Aanval (aantal) %<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>1q21.1 deletie<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">47<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(11) 23%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(17) 36%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(3) 6%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>1q21.1 duplicatie<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">45<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(13) 29%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(15) 33%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(3) 7%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>16p11.2 deletie<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">156<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(50) 32%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(76) 49%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(42) 27%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>Distale 16p11.2 deletie<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">10<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(2) 20%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(5) 50%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(1) 10%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>ADNP<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">16<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(11) 69%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(14) 88%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(4) 25%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>ASXL3<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">16<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(11) 69%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(14) 88%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(4) 25%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>CHAMP1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">19<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(4) 21%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(13) 68%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(3) 16%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>CSNK2A1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">21<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(6) 29%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(18) 86%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(8) 38%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>CTNNB1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">31<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(4) 13%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(22) 71%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(0) 0%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>DYRK1A<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">22<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(10) 45%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(17) 77%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(11) 50%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>GRIN2B<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">42<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(11) 26%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(33) 79%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(7) 17%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>HIVEP2<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">15<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(5) 33%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(11) 73%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(1) 7%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>HNRNPH2<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">19<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(3) 16%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(19) 100%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(4) 21%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>MED13L<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">19<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(9) 47%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(17) 89%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(1) 5%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>PACS1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">20<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(10) 50%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(19) 95%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(9) 45%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>PPP2R5D<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">58<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(19) 33%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(51) 88%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(27) 47%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>SCN2A<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">83<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(36) 43%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(68) 82%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(63) 75%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>SETBP1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">17<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(3) 18%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(10) 59%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(1) 6%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>SLC6A1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">37<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(12) 32%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(27) 73%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(30) 81%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>STXBP1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">64<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(23) 36%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(49) 77%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(54) 84%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>SYNGAP1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">30<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(15) 50%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(23) 77%<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">(23) 77%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p>De tweede tabel<strong>(Tabel 2<\/strong>) bevat genetische groepen met 5 tot 9 afgeronde medische geschiedenisinterviews. Deze tabel geeft een overzicht van het totale aantal mensen met een autismespectrumstoornis (ASS), ontwikkelingsachterstand of verstandelijke beperking (DD\/ID) en epileptische aanvallen. Met meer informatie en deelnemers zullen we een beter klinisch beeld kunnen schetsen van deze genetische aandoeningen.<\/p>\n<p><strong>Tabel 2. Genetische groepen met 5 tot 9 MHI&#8217;s voltooid (7 groepen).<\/strong><\/p>\n<table style=\"width: 100%; border: 1px solid black;\">\n<tbody>\n<tr>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>Gen-\/kopienummervariant<\/strong><\/td>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>Aantal mensen met MHI&#8217;s<\/strong><\/td>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>ASD-nummer<\/strong><\/td>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>DD\/ID-nummer<\/strong><\/td>\n<td style=\"color: white; background-color: #f36046; text-align: center; padding: 5px; border: 1px solid #d9d9d9;\"><strong>Aantal inbeslagnames<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>7q11.23 duplicatie<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">6<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">4<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">4<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">2<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>ARID1B<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">6<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">1<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">4<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">0<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>CHD2<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">8<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">6<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">5<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">8<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>CHD8<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">6<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">6<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">5<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">0<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>FOXP1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">6<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">3<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">3<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">2<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>GRIN1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">6<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">1<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">6<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">3<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 5px; border: 1px solid #d9d9d9;\"><strong>PTCHD1<\/strong><\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">5<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">1<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">4<\/td>\n<td style=\"text-align: center; padding: 5px; border: 1px solid #d9d9d9;\">1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In de afgelopen 10 jaar heeft Simons Searchlight zich ontwikkeld en omvat nu meer dan 150 genetische aandoeningen. Als onderdeel van ons 10-jarig onderzoek kijken we naar de deelnemers binnen onze gemeenschap. &#8220;Door de nauwe samenwerking met gezinnen in al onze aandoeningen in de afgelopen 10 jaar, zien we \u00e9\u00e9n ding: hoewel elk kind een [&hellip;]<\/p>\n","protected":false},"author":18,"featured_media":42468,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[273],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/posts\/42442"}],"collection":[{"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/comments?post=42442"}],"version-history":[{"count":1,"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/posts\/42442\/revisions"}],"predecessor-version":[{"id":42473,"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/posts\/42442\/revisions\/42473"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/media\/42468"}],"wp:attachment":[{"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/media?parent=42442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/categories?post=42442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.simonssearchlight.org\/nl\/wp-json\/wp\/v2\/tags?post=42442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}